LFCR Stock Analysis: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$4.42
0.06 (1.38%)
▲
5d:
+2.08%
30d:
-16.13%
90d:
-12.82%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LFCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LFCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $4.42, which is considered oversold relative to its 30-day fair value range of $4.43 to $5.06.
Technical Outlook: Technically, LFCR is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $4.96.
Market Sentiment: LFCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.83 (+56.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LFCR is showing sideways momentum. Immediate support is located at $4.23, while resistance sits at $4.96.
Market Sentiment: LFCR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.83 (+56.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.43 -
$5.06
Company Quality Score
46/100
(HOLD)
Options IV Signal
45th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 45th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.7% below Wall St target ($6.83)
Trading Range Analysis
30-Day Trading Range
$4.43 -
$5.06
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.61
(13.9%)
Support & Resistance Levels
Support Level
$4.23
Resistance Level
$4.96
Current Trend
Sideways
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.00
Wall Street Target
$6.83
(+56.7%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: August 03, 2026 2:22 AM ET
Data refreshes hourly during market hours. Next update: 3:22 AM
Data refreshes hourly during market hours. Next update: 3:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
